Does Pfizer's COVID-19 Vaccine Make the Big Pharma Stock a Buy?

Investors have reason to be excited after the update from Pfizer and BioNTech. Researchers evaluating the efficacy of COVID-19 vaccine candidates especially look for the production of antibodies that bind to the novel coronavirus and antibodies that neutralize the virus. Seven days after the second dosing of the vaccine, all participants who took the 10-microgram or 30-microgram dose had significantly elevated binding antibodies and neutralizing antibodies.